Green Fresh Biotechnology Company Limited Overview
Green Fresh Biotechnology is a vertically focused, Fujian-based manufacturer of seaweed- and plant-derived hydrocolloids: agar-agar, refined and semi-refined carrageenan, konjac gum, and custom blended texturant systems. It sells to food processors and trading houses in roughly 50/50 domestic and export proportions. A Frost & Sullivan report commissioned by the company (March 2025) ranks it first in China by sales value, volume and share among producers of agar-agar and refined/semi-refined carrageenan, and as the largest global manufacturer of these products in 2020–21 and 2023–24. Its 27,390-tonne design capacity spans Zhangzhou, Quanzhou, Hubei (konjac), Xiamen (agarose microspheres) and Indonesia (semi-refined carrageenan). The equity story has moved from a 2022 commodity-price windfall, through a 2023 inventory write-down loss, to a thin-margin, highly levered recovery. Management is reframing the group as a "biotechnology" company through higher-value blends, quick-dissolve agar, agarose for life sciences and a nascent 100% biodegradable seaweed-film business.
Company's own description (FY2025 AR, Corporate Overview)
The FY2025 AR describes the company as a global leader in the technical development and manufacturing of "all-natural performance materials". Its main products are:
-
agar-agar and carrageenan made from naturally bred seaweed;
-
konjac gum made from naturally bred konjac;
-
blended products with extended functions created by combining different colloids and gums, together with professional solutions built on them.
The primary applications are processed foods: processed meat, confectionery, dairy, sauces, bakery, pet food and, increasingly, flavoured tea beverages. Beauty and household uses include 100% biodegradable face masks and gel air fresheners, and the company is entering plastic-alternative wrapping and soil film. Agarose and agarophyte products, made through more complex processes, serve as laboratory culture media and electrophoresis media for genetic sequencing.
The company also describes itself as a long-term partner to customers, both in raw-material supply and in parts of their product development. It positions this co-development as a deliberate strategy to secure orders (FY2024 ARA; FY2025 ARA, "Business Development Strategy").
Independent characterisation
In substance, Green Fresh is a B2B specialty-ingredient processor operating at the commodity end of the texturant value chain.
Earnings drivers: Roughly 73–85% of revenue (73.3% in FY2025; 85.8% in FY2023) comes from two seaweed-derived extracts, carrageenan and agar. Their prices are set largely by the global price of red seaweed (Eucheuma/Kappaphycus for carrageenan; Gracilaria/Gelidium for agar). The FY2022–FY2025 record shows that group earnings are a function of the seaweed price cycle and inventory timing more than of volume growth.
-
FY2022: rising seaweed prices produced record gross profit of RMB384.1m.
-
FY2023: falling seaweed prices forced a RMB142.4m inventory write-down and a loss.
-
FY2024: release of that provision on sale lifted margins.
-
FY2025: continued price deflation compressed carrageenan margins again.
Higher-value tier: Blended products, quick-dissolve agar, konjac and agarose microspheres carry higher or more stable margins. Together they were about 25% of revenue in FY2025.
Business model and revenue model
| Dimension | Characterisation (FY2025 basis) |
|---|---|
| Revenue model | ~100% product sales, recognised at a point in time on delivery (FY2025 ARA note 3). No subscription, licensing or service revenue is disclosed. |
| Pricing | Contract prices net of VAT. Credit terms up to 180 days. Contract liabilities (advances) of RMB7.2m at FY2025. |
| Product vs service mix | Product ~100%. Application/formulation support is bundled, not separately billed. |
| Value chain position | Midstream: buys dried seaweed and konjac (top-5 suppliers 53.0% of purchases; largest 16.6%, FY2025) → extraction/refining → powders and blends → sells to food manufacturers and trading companies. |
| Customer types | Food manufacturers (meat, dairy, confectionery, bakery, beverages, pet food), ingredient traders/distributors, cosmetics/household manufacturers, and life-science users (agarose). Top-5 customers 24.9% of revenue; largest 8.0% (FY2025). |
| End-markets | Processed food (dominant), beverages (tea "chewing contents"), pet food, personal care (masks), household (air-freshener gels), biomedical/lab (agarose), packaging/agriculture (algae membrane, nascent). |
| Geography | Chinese Mainland 48.1%; overseas 51.9% (Europe 26.0%, Asia ex-China 17.9%, South America 5.3%, North America 2.3%, Africa 0.5%) — FY2025. |
Strategy
Stated strategy themes (FY2024 and FY2025 ARAs and ARs)
-
"Long-term partner" model. Embed in customers' raw-material supply chains and co-develop applications to secure orders.
-
Product-technology upgrading. Shift the mix toward higher-technology, higher-margin products: blended solutions, quick-dissolve agar, deep-processed bakery carrageenan, konjac fibres and agarose/microspheres.
-
Application diversification. Extend beyond food into household (gel air fresheners), skincare (biodegradable masks), and plastic alternatives (algae membrane wrapping and soil films). Management frames this as a decarbonisation opportunity "for the coming decades".
-
Geographic diversification of production. Expand and upgrade PT Hongxin in Indonesia for cost advantage, proximity to seaweed resources and potential tax efficiency on sales originating from Indonesia.
-
Overseas sales-network build-out. Add overseas sales representatives and trade-show presence (S&D +25.7% in FY2025), particularly for blended products.
-
Rebranding as biotechnology. The 2025 name change was justified by seaweed's carbon-negative growth profile and its role as an alternative to fossil-fuel-based materials.
-
Dividend continuity. A "target dividend payout each year after considering available resources" (HK1.2c in both FY2024 and FY2025), paid out of share premium.
Initiatives in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Date | Detail | Status |
|---|---|---|---|
| Blue Ocean algae-membrane recapitalisation with local state-linked investor | 31 Oct 2024 | Xinwan Investment (Longhai District) up to RMB63.85m; group injects RMB27.77m; group stake 46.68% | Completed (registration of capital injection) |
| Certification programme for biodegradable film | May–Dec 2025 | FDA food-contact assessment; SGS Bio-Based and No Plastic; home compostability | Achieved; commercial revenue not disclosed |
| Beverage "chewing contents" capacity | Aug 2024 – Feb 2026 | HK$6.5m allocated from placement; HK$4.8m used by end-FY2025 | In progress |
| Corporate rebrand to Green Fresh Biotechnology | Jun–Jul 2025 | Name and stock short name change | Completed |
| PT Hongxin facility enhancement | Ongoing | Quality and cost upgrades; capacity expansion planned, internally funded | Ongoing (capex RMB47–48m p.a. group-wide) |
| Competitive pricing strategy for carrageenan | 1H2026 | Volume-led share recapture; carrageenan revenue +49% | Delivered revenue; margin compressed to 14.2% |
| Inventory turnover and cost-saving measures | 2,026 | Part of the going-concern mitigation plan | Inventory −7.7% in 1H2026 |
| Covenant management | Dec 2025 onward | Waivers on RMB125.6m; continued facility renewals | Ongoing |
Medium-term targets and guidance
No quantitative medium-term financial targets or formal guidance (revenue, margin, ROE, leverage) are published. Management's qualitative outlook (FY2025 AR) expects:
-
carrageenan prices to "bottom out and gradually rise" with the business cycle;
-
PRC sales to improve;
-
the blended-product uptrend to continue.
Products & Services
Prices are not publicly disclosed for any product; all are sold B2B on contract. Brand names for individual SKUs are not disclosed in the filings reviewed.
Agar-agar segment
| Product | Description & capabilities | Target customers | Launch / milestone | Notes |
|---|---|---|---|---|
| Conventional agar-agar (food grade) | Gelling agent from red seaweed (Gracilaria/Gelidium); heat-stable gels; soluble dietary fibre | Jelly, confectionery, desserts, bakery fillings, health foods | Agar lines since the 2012 Lvqi merger | Covered by GB1886.239-2016, which the group helped draft |
| Quick-dissolve agar-agar | Deep-processed agar that dissolves at lower temperature/faster; used in yoghurt and dairy | Dairy manufacturers (China) | Marketed via Lvqi Trading (Shanghai) from 2018; +capacity 2019 | Management repeatedly cites it as one of the highest-margin products (FY2021–FY2025 ARs) |
| Agarose | High-purity agar fraction for laboratory culture media and electrophoresis in genetic sequencing | Life-science labs, diagnostics, reagent distributors | IPO proceeds earmarked for 50 t agarose capacity (Longhai) | Small revenue; not separately disclosed |
| Agarose microspheres / agar gel microspheres | Separation medium (chromatography) for biomedical production processes | Biopharma process users | Production commenced 2022; Xiamen Sanji base, 10 t/yr | Highest-technology product; revenue not disclosed |
| Agarophyte products | Processed agarophyte seaweed materials | Industrial / lab | IPO plan (200 t) | — |
Carrageenan segment
| Product | Description & capabilities | Target customers | Launch / milestone | Notes |
|---|---|---|---|---|
| Refined carrageenan (kappa/iota/lambda grades) | Thickener, gelling agent, stabiliser; water retention in meat; suspension in dairy | Processed meat, dairy, confectionery, sauces, pet food; European and Asian food majors and traders | Lvbao since 2001; Green Fresh (Fujian) since 2007 | FY2025 refined carrageenan volume −10.7%, ASP −5.1% |
| Refined iota carrageenan | Elastic gels, freeze–thaw stability | Dairy desserts, meat | IPO plan for 180 t/yr | — |
| Semi-refined carrageenan (SRC/PES) | Lower-cost alkali-treated seaweed carrageenan | Pet food, meat, industrial users | PT Hongxin (Indonesia) acquired Apr 2021, 4,300 t/yr | Cost and seaweed-proximity advantages |
| Deep-processed carrageenan for bakery | Application-tailored grades for bakery | Bakery manufacturers | Highlighted FY2023–FY2025 | Cited as a margin-enhancing growth product |
Konjac segment
| Product | Description & capabilities | Target customers | Launch / milestone | Notes |
|---|---|---|---|---|
| Konjac gum (glucomannan) | High-viscosity soluble fibre; gelling with carrageenan/xanthan | Health foods, low-calorie foods, jellies, plant-based meat texture | Shiyanhaiyi since 2012; +1,500 t Fujian line 2019 | FY2025 revenue +54.3%; margin 14.9% |
| Konjac blends for plant-based meat | Gives meat-like mouthfeel | Alt-protein producers | Cited FY2021 AR | — |
| OEM fibre-rich health foods | OEM manufacturing of fibre products for personal consumption | Health-food brands | Started per FY2021 AR | Scale not disclosed |
Blended products segment
| Product | Description & capabilities | Target customers | Launch / milestone | Notes |
|---|---|---|---|---|
| Custom blended texturant systems | Ready-to-use mixtures of carrageenan, agar, konjac and other gums tailored to function (gel strength, water binding, syneresis control) | Meat processors, dairy, beverages, desserts; overseas networks being built | Lvbao blends since 2000s; 3,300 t/yr capacity | Sales-volume CAGR of more than 20% over 2021–2025 (FY2025 AR); revenue CAGR 17% over 2021–2024 (FY2024 ARA) |
| "Chewing contents" for flavoured beverages | Ready-to-use gel pieces/inclusions for tea drinks | New-style tea chains and beverage makers | HK$6.5m of 2024 placement proceeds earmarked; HK$1.7m unused at end-FY2025 | Trend-linked, China-centric |
Others / non-food and new materials
| Product | Description & capabilities | Target customers | Launch / milestone | Notes |
|---|---|---|---|---|
| Gel-type air fresheners | Carrageenan/agar-based gel matrices | Household products makers | Developed FY2023–FY2025 | — |
| 100% biodegradable face-mask substrates | Seaweed-based mask sheets | Cosmetics brands | Developed FY2023–FY2025 | — |
| 100% biodegradable algae membrane (wrapping film, seasoning/food packing film, soil film) | Seaweed-based plastic alternative; FDA food-contact assessment passed (May 2025); SGS 100% Bio-Based (Aug 2025) and No Plastic (Oct 2025) certifications; home-compostability compliance (Dec 2025) | Food/seasoning packaging, cosmetics packaging, agricultural mulch | Blue Ocean set up Jul 2023; HK$16.2m of the 2024 placement fully deployed | Pre-commercial scale; revenue not disclosed |
| Seaweed / algae powder trading | Trading of seaweed powder | Various | "Others" segment | RMB14.8m in FY2025 |
Financial Narrative
Income statement
Sources: FY2022–FY2025 from the FY2023, FY2024 and FY2025 ARAs (FY2022 restated in RMB). FY2021 revenue, gross profit, net profit and diluted EPS come from the FY2025 AR five-year highlights. The other FY2021 lines are converted from FY2021 AR HK$ figures (S&D HK$16.7m, admin HK$92.8m, finance costs HK$22.6m, tax HK$33.7m, attributable HK$103.6m) at RMB0.830/HK$, with operating profit derived as PBT plus net finance cost.
FY2022 DPS is HK2c interim plus HK3c final.
Margins and growth
Revenue CAGR FY2021–FY2025: −1.6% p.a. (computed: 965.6 → 904.7). In HK$ terms, revenue was HK$887.2m in FY2020 and HK$1,163.1m in FY2021.
Revenue and gross profit — trends and drivers.
FY2022: Revenue peaked as post-COVID restocking and natural-resource inflation drove carrageenan prices sharply higher (carrageenan revenue +65.7%).
FY2023: Customers cut safety stocks and European demand slowed, so carrageenan prices fell. Export volumes of carrageenan and agar dropped 20.7%. The group was holding seaweed bought at peak prices, which forced a RMB142.4m net-realisable-value provision. Gross margin collapsed to 3.2%; excluding the provision it would have been 15.3%, per management.
FY2024: RMB131.8m of the prior provision was released as the underlying inventory was sold, which flattered gross margin (22.5%) and turned the group profitable.
FY2025: Seaweed and carrageenan prices kept falling. Refined carrageenan volume fell 10.7% and ASP 5.1%; agar volume fell 13.3% and ASP 1.4%. Gross margin slipped to 18.5% and net income almost disappeared.
Operating costs.
-
Opex rose every year: S&D +86% and admin +21% from FY2022 to FY2025. Drivers were overseas sales hires, trade shows, salary increments and R&D materials for algae membranes.
-
This creates negative operating leverage in a falling-price environment.
-
Finance costs peaked at RMB40.9m in FY2023 as HKD/USD rates rose, and have eased with lower RMB rates (weighted average rate 4.59% FY2022 → 5.73% FY2023 → 5.22% FY2024 → 4.57% FY2025).
Balance sheet
Sources: FY2025, FY2024 and FY2023 ARAs. FY2021 is the restated RMB balance sheet at 1 Jan 2022 from the FY2023 ARA. FY2024 and FY2025 long-term borrowings include unsecured third-party loans of RMB17.0m and RMB18.4m respectively. No separately disclosed goodwill line exists; the intangible assets line is shown.
Commentary.
Asset quality: The balance sheet is dominated by inventory: RMB838.3m, 51% of total assets and 75% of current assets at FY2025. Inventory has stayed far above pre-2022 levels despite three years of falling revenue.
Funding structure: Debt is short-dated and bank-funded: 84% of borrowings are due within 12 months, all at variable rates. Some debt is secured on land and buildings (carrying value RMB81.4m) and guaranteed by the Chairman (RMB70.3m unsecured facilities guaranteed by Chan Kam Chung and RMB10.0m by Guo Dongxu).
Covenants: In December 2025 the group needed one-time covenant waivers on RMB125.6m of debt. The auditor-approved accounts include an explicit going-concern basis-of-preparation note relying on continued waivers and facility renewals.
Cash flow
Sources: FY2025 ARA going-concern note (cash inflow from operations RMB128.7m in FY2024 and RMB7.0m in FY2025); capex from FY2023–FY2025 ARAs; FY2021 capex HK$77.5m converted.
1H2026: net operating cash flow RMB123m (+739.5% YoY), financing −RMB53.0m, investing −RMB2.1m (1H2026 report summary).
Commentary. Cash generation is highly sensitive to inventory build.
-
FY2025's RMB90.6m inventory increase absorbed almost all operating cash.
-
In 1H2026 inventory fell 7.7% and operating cash flow recovered to RMB123m. Part of this went to cut short-term debt (−6%) and long-term debt (−9.9%), and cash rose 55.8%.
-
No buyback programme exists beyond small trustee purchases for the share award scheme.
Ratios (computed, year-end basis)
Notes: FY2023 DIO is understated because cost of sales includes the RMB142.4m provision. Net debt/EBITDA is not meaningful for FY2023 (negative EBITDA). Company-reported gearing for FY2021 (36.0%) is as reported in HK$.
Ratio commentary.
-
Returns have structurally fallen from the FY2022 super-cycle: ROIC went from 15.6% to 2.0%.
-
Leverage worsened sharply on an earnings basis (net debt/EBITDA 5.8x; interest cover 1.2x) even though book gearing looks stable. This is what triggered the covenant waivers.
-
The cash conversion cycle of almost 400 days is extreme even for a seaweed processor, which must buy harvests seasonally. It is the single most important balance-sheet risk.
-
The 1H2026 report shows some relief: liabilities/assets 47.4%, interest-bearing debt/assets 34.5%, current ratio 1.71, quick ratio 0.5.
Interim snapshot
1H2026 gross profit is computed from the reported 14.16% margin. 1H2026 net profit is approximate, from the −0.56% net margin.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (CNY Mn)
| Segment revenue (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Agar-agar | 241.9 | 322.0 | 298.7 | 294.9 | 252.1 |
Carrageenan | 569.3 | 943.6 | 708.3 | 487.3 | 410.6 |
Konjac products | 57.7 | 46.2 | 42.5 | 57.5 | 88.7 |
Blended products | 71.2 | 93.5 | 124.3 | 138.4 | 138.5 |
Others | 25.5 | 5.6 | 0.2 | 11.1 | 14.8 |
Total revenue | 965.6 | 1,410.9 | 1,174.0 | 989.3 | 904.7 |
Segment gross profit (CNY Mn)
| Segment gross profit (CNY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Agar-agar | 100.6 | 93.1 | 88.2 | 72.4 |
Carrageenan | 245.8 | -96.8 | 82.9 | 38.8 |
Konjac products | 5.1 | 4.7 | 7.5 | 13.3 |
Blended products | 31.6 | 36.7 | 39.4 | 37.6 |
Others | 1.0 | 0.0 | 4.4 | 5.2 |
Total gross profit | 384.1 | 37.6 | 222.5 | 167.2 |
Segment gross margin (%)
| Segment gross margin (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Agar-agar | 31.2 | 31.2 | 29.9 | 28.7 |
Carrageenan | 26.1 | -13.7 | 17.0 | 9.4 |
Konjac products | 11.1 | 11.0 | 13.1 | 14.9 |
Blended products | 33.8 | 29.5 | 28.5 | 27.2 |
Group | 27.2 | 3.2 | 22.5 | 18.5 |
Segment YoY revenue growth (%)
| Segment YoY revenue growth (%) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Agar-agar | 33.1 | -7.2 | -1.3 | -14.5 |
Carrageenan | 65.7 | -24.9 | -31.2 | -15.7 |
Konjac products | -19.9 | -8.0 | 35.3 | 54.3 |
Blended products | 31.3 | 33.0 | 11.3 | 0.0 |
Group | 46.1 | -16.8 | -15.7 | -8.6 |
Segment share of revenue (%)
| Segment share of revenue (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Agar-agar | 25.1 | 22.8 | 25.4 | 29.8 | 27.9 |
Carrageenan | 59.0 | 66.9 | 60.3 | 49.3 | 45.4 |
Konjac products | 6.0 | 3.3 | 3.6 | 5.8 | 9.8 |
Blended products | 7.4 | 6.6 | 10.6 | 14.0 | 15.3 |
Others | 2.6 | 0.4 | 0.0 | 1.1 | 1.6 |
Segment revenue (CNY Mn) (1H2025–1H2026)
| Segment revenue (CNY Mn) | 1H2025 | 1H2026 |
|---|---|---|
Carrageenan | 186.1 | 278.0 |
Agar-agar | 124.7 | 129.0 |
Blended products | 55.3 | 68.6 |
Konjac products | 35.9 | 52.9 |
Others | 8.0 | 6.1 |
Total | 410.0 | 535.0 |
Income Statement and Per-Share Data
| Metric (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 965.6 | 1,410.9 | 1,174.0 | 989.3 | 904.7 |
Cost of sales | 741.1 | 1,026.8 | 1,136.4 | 766.8 | 737.5 |
Gross profit | 224.5 | 384.1 | 37.6 | 222.5 | 167.2 |
Selling & distribution expenses | 13.9 | 13.8 | 17.8 | 20.6 | 25.9 |
Administrative expenses | 77.0 | 91.1 | 97.3 | 104.6 | 110.5 |
Operating profit | 132.8 | 289.2 | -72.4 | 110.2 | 34.6 |
D&A (land use rights, PP&E, intangibles) | — | 49.5 | 46.8 | 48.0 | 47.4 |
EBITDA (computed) | — | 338.7 | -25.6 | 158.2 | 82.0 |
Finance costs | 18.8 | 27.7 | 40.9 | 30.1 | 27.7 |
Pre-tax income | 114.2 | 261.6 | -112.9 | 80.9 | 7.1 |
Income tax | 28.0 | 61.7 | -27.4 | 20.0 | 1.8 |
Net income | 86.3 | 199.9 | -85.4 | 60.9 | 5.4 |
Net income attributable to owners | 86.0 | 199.2 | -85.3 | 62.2 | 6.6 |
EPS basic (MYR Bn) | — | 0.242 | -0.103 | 0.074 | 0.008 |
EPS diluted (MYR Bn) | 0.102 | 0.240 | -0.103 | 0.074 | 0.008 |
Dividend per share (HK cents) | — | 5.0 | 0.0 | 1.2 | 1.2 |
Margin Analysis (%)
| Metric (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth YoY | — | 46.1 | -16.8 | -15.7 | -8.6 |
Gross margin | 23.2 | 27.2 | 3.2 | 22.5 | 18.5 |
Operating margin | 13.8 | 20.5 | -6.2 | 11.1 | 3.8 |
EBITDA margin | — | 24.0 | -2.2 | 16.0 | 9.1 |
Net margin | 8.9 | 14.2 | -7.3 | 6.2 | 0.6 |
Effective tax rate | 24.5 | 23.6 | 24.3 | 24.7 | 24.6 |
Balance Sheet
| Metric (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 1,389.6 | 1,691.0 | 1,543.6 | 1,572.3 | 1,632.3 |
Property, plant & equipment | 412.2 | 401.4 | 374.9 | 372.9 | 362.1 |
Land use rights | 55.9 | 54.9 | 53.9 | 52.6 | 50.8 |
Intangible assets (incl. any goodwill) | 72.4 | 67.9 | 66.9 | 67.1 | 63.7 |
Inventories | 562.1 | 906.2 | 785.0 | 747.7 | 838.3 |
Trade & other receivables | 162.6 | 208.3 | 127.3 | 149.5 | 166.8 |
Cash & equivalents (unrestricted) | 109.4 | 37.7 | 72.6 | 120.7 | 88.6 |
Restricted cash | 0.0 | 1.1 | 11.7 | 20.7 | 19.7 |
Short-term borrowings | 408.9 | 491.3 | 532.0 | 460.6 | 488.9 |
Long-term borrowings | 77.0 | 88.6 | 67.2 | 101.0 | 96.1 |
Total borrowings | 486.0 | 579.9 | 599.1 | 561.6 | 585.0 |
Lease liabilities | 6.6 | 4.5 | 2.9 | 3.5 | 7.8 |
Net debt (borrowings − cash − restricted cash) | 376.6 | 541.2 | 514.8 | 420.2 | 476.6 |
Total equity | 704.7 | 852.2 | 754.1 | 850.1 | 847.1 |
Equity attributable to owners | 688.4 | 844.6 | 745.2 | 839.9 | 838.7 |
Current assets | 838.6 | 1,153.3 | 996.7 | 1,038.7 | 1,113.5 |
Current liabilities | 575.0 | 723.0 | 697.1 | 595.8 | 663.0 |
Working capital (net current assets) | 263.6 | 430.3 | 299.6 | 442.9 | 450.5 |
Cash Flow and Balance Sheet
| Metric (CNY Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash generated from operations | — | — | — | 128.7 | 7.0 |
Capital expenditure | 64.3 | 43.4 | 11.8 | 48.0 | 47.4 |
Free cash flow (computed: operations − capex) | — | — | — | 80.7 | -40.4 |
Dividends paid | — | 32.1 | 22.4 | 0.0 | 9.5 |
Share purchases by award trust (HKD Mn) | 0.3 | 0.0 | 0.5 | 0.0 | 1.1 |
New equity issued (HKD Mn net) | 0.0 | 0.0 | 0.0 | 32.3 | 0.0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) attributable NI / year-end attributable equity | 12.5 | 23.6 | -11.4 | 7.4 | 0.8 |
ROA (%) NI / total assets | 6.2 | 11.8 | -5.5 | 3.9 | 0.3 |
ROIC (%) OP×(1−25%) / (equity + net debt) | 9.2 | 15.6 | -4.3 | 6.5 | 2.0 |
Current ratio (x) | 1.46 | 1.60 | 1.43 | 1.74 | 1.68 |
Debt / equity (x) | 0.69 | 0.68 | 0.79 | 0.66 | 0.69 |
Gearing per company (%) net debt / (net debt + equity) | 36.0 | 39.1 | 41.2 | 34.3 | 37.3 |
Net debt / EBITDA (x) | — | 1.6 | — | 2.7 | 5.8 |
Interest coverage (x) OP / finance costs | 7.1 | 10.4 | -1.8 | 3.7 | 1.2 |
Asset turnover (x) | 0.69 | 0.83 | 0.76 | 0.63 | 0.55 |
Days inventory outstanding | 277 | 322 | 252 | 356 | 415 |
Days sales outstanding (trade receivables) | — | 39 | 27 | 42 | 49 |
Days payables outstanding (trade payables) | — | 49 | 33 | 44 | 66 |
Cash conversion cycle (days) | — | 312 | 246 | 354 | 398 |
Income Statement and Margin Analysis (%)
| Metric (CNY Mn) | 1H2023 | 1H2024 | 1H2025 | 1H2026 |
|---|---|---|---|---|
Revenue | 582.9 | 459.0 | 410.0 | 535.0 |
Gross profit | 106.1 | 98.8 | 60.1 | 75.8 |
Gross margin (%) | 18.2 | 21.5 | 14.7 | 14.2 |
Net profit | 25.1 | 22.6 | -12.3 | -3.0 |
Attributable profit | 25.0 | — | -12.1 | -1.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRegion revenue (CNY Mn)
| Region revenue (CNY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Chinese Mainland | 582.9 | 595.2 | 475.2 | 434.9 |
Europe | 470.7 | 291.6 | 286.2 | 235.1 |
Asia excluding Chinese Mainland | 237.9 | 209.8 | 161.7 | 161.7 |
South America | 62.6 | 50.6 | 42.1 | 47.8 |
North America | 52.4 | 23.6 | 20.6 | 20.4 |
Africa | 4.2 | 3.0 | 3.2 | 4.6 |
Oceania | 0.1 | 0.1 | 0.2 | 0.1 |
Total | 1,410.9 | 1,174.0 | 989.3 | 904.7 |
Region YoY growth (%)
| Region YoY growth (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Chinese Mainland | 2.1 | -20.2 | -8.5 |
Europe | -38.0 | -1.9 | -17.8 |
Asia excluding Chinese Mainland | -11.8 | -22.9 | 0.0 |
South America | -19.1 | -16.9 | 13.6 |
North America | -54.9 | -12.7 | -1.1 |
Africa | -29.4 | 8.1 | 43.1 |
Region share of revenue (%)
| Region share of revenue (%) | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|
Chinese Mainland | 47.9 | 41.3 | 50.7 | 48.0 |
Overseas | 52.1 | 58.7 | 49.3 | 52.0 |
Region non-current assets (CNY Mn)
| Region non-current assets (CNY Mn) | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Chinese Mainland | 448.2 | 423.5 | 424.7 | 413.9 |
Hong Kong | 1.2 | 0.4 | 1.5 | 0.9 |
Indonesia | 76.3 | 75.2 | 70.7 | 63.5 |
Share Price History
| Date | Price (HKD) | Context / source |
|---|---|---|
17 Oct 2019 | 1.16 | IPO price |
Early Dec 2022 | 3.54 | Close before 5 Dec 2022 share-award grant (FY2025 AR) — near the cycle peak |
20 May 2024 | 0.77 | Close before 21 May 2024 share-award grant |
5 Aug 2024 | 0.78 | Close before placement (placed at HK$0.81) |
30 Dec 2025 | 0.62 | ET Net quote |
23 Feb 2026 | 0.64 | ET Net quote |
17 Jul 2026 | 0.72 | Google Finance (market cap HK$629m; 52-week range 0.57–0.79) |
31 Jul 2026 | 0.68 | StockAnalysis quote |
Return metric (%) | 1-year | 3-year |
Share price change | -12.5 | -82.4 |
Valuation Snapshot
| Multiple | Value | Basis |
|---|---|---|
P/E (TTM) | 28.4x | 28 Sep 2026 close (10jqka / CSJ). TTM attributable profit ≈ RMB17.3m (computed) |
P/B | 0.59x | 28 Sep 2026 |
P/S (TTM) | 0.48x | 28 Sep 2026 |
EV/Sales (FY2025) | ~1.1x | Computed: market cap ~RMB490m + FY2025 net debt RMB476.6m + NCI RMB8.4m ≈ RMB975m |
EV/EBITDA (FY2025) | ~11.9x | Computed: EV ~RMB975m / EBITDA RMB82.0m |
Dividend yield | ~1.7–1.9% | HK1.2c on a HK$0.62–0.72 price |
Dividend (HK cents/share)
| Dividend (HK cents/share) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim | — | 2.0 | 0.0 | 0.0 | 0.0 |
Final | 2.5 | 3.0 | 0.0 | 1.2 | 1.2 |
Total cash paid in year (CNY Mn) | — | 32.1 | 22.4 | 0.0 | 9.5 |
Debt maturity (CNY Mn, 31 Dec 2025)
| Debt maturity (CNY Mn, 31 Dec 2025) | Amount |
|---|---|
Bank borrowings due within 1 year | 488.9 |
Bank borrowings due after 1 year | 77.8 |
Third-party loan (unsecured, fixed rate) due after 1 year | 18.4 |
Lease liabilities — within 1 year | 1.8 |
Lease liabilities — after 1 year | 6.0 |
Total borrowings and leases | 592.8 |
Analyst Conclusions
Management guidance
There is no numeric guidance. Qualitative outlook (FY2025 AR, 30 Mar 2026):
-
carrageenan prices to bottom out and gradually rise;
-
PRC sales to improve;
-
the blended-product uptrend to continue;
-
continued investment in PT Hongxin;
-
strong long-term demand for hydrocolloids across food, household, skincare and biodegradable seaweed products.
The 12 Aug 2026 update attributes 1H2026 improvement to carrageenan volume gains from a competitive pricing strategy.
Consensus
Not available (no coverage identified).
Bull case
-
Cyclical trough and operating leverage. 1H2026 revenue rose 30.5% to RMB535m while the attributable loss narrowed to RMB1.4m. If carrageenan prices stabilise while volumes hold, every 5 points of gross margin on a ~RMB1.0–1.1bn run-rate adds about RMB50m of gross profit. That is roughly ten times FY2025 net profit.
-
Inventory release and deleveraging. Inventory fell 7.7% in 1H2026 and operating cash flow reached RMB123m. Continuing to bring the ~400-day cash conversion cycle back toward FY2023's ~250 days could release more than RMB200m of cash, reduce net debt/EBITDA below 3x and remove covenant risk.
-
Deep value with option value. The stock trades at 0.59x book. On top of the core business, there are unpriced options in agarose microspheres and certified biodegradable films, the latter backed by a local-government investor.
Bear case
-
Structural price deflation, not a cycle. Carrageenan ASPs fell for three consecutive years, and 1H2026 volume was bought with price (gross margin 14.2%, below FY2025's 18.5%). Domestic "involution" may keep margins structurally low.
-
Refinancing fragility. 84% of debt is current, interest cover is 1.2x (FY2025), covenant waivers were needed, and the accounts carry a going-concern note. A bank pulling facilities in a weak half could force dilutive equity or distressed inventory sales.
-
Governance and minority-shareholder risk. The controlling family holds 67%, the Chair/CEO roles are combined, there is no research coverage, liquidity is thin, distributable reserves are only RMB77.2m, and there is a prior Model Code breach. These factors argue for a persistent discount regardless of operational recovery.
Catalysts and monitorables (next 12 months)
-
FY2026 annual results (expected around late March 2027): full-year profitability, gross-margin trajectory and dividend.
-
Whether covenant waivers recur at end-FY2026, and the terms of facility renewals.
-
Seaweed and carrageenan price indicators (Indonesia and Philippines) and European demand.
-
Inventory and DIO trend; operating cash flow in 2H2026.
-
First disclosed revenue from algae membrane or agarose microspheres; Blue Ocean funding milestones.
-
PT Hongxin capacity expansion and capex.
-
The outcome of Ingredion's proposal for Tate & Lyle and its implications for global pricing.
-
Any change in the controlling shareholders' stakes, or a privatisation proposal (speculative; none announced).
Analyst verdict
Green Fresh Biotechnology is a genuine scale player in a niche but essential ingredient chain. It is China's largest agar and refined/semi-refined carrageenan producer by its commissioned rankings, with a cost-advantaged Indonesian plant and a credible portfolio of adjacent higher-value products. Yet the FY2021–FY2026 record shows a business whose economics are governed by seaweed prices and inventory timing rather than by pricing power or proprietary technology.
The FY2022 windfall (net profit RMB199.9m) was followed by a provision-driven loss in FY2023. FY2024's flattering recovery was itself partly an accounting release of earlier provisions. FY2025's near-zero profit (RMB5.4m) is the cleaner read on underlying earnings power in a deflationary market.
The balance sheet is the crux. Almost RMB840m of inventory sits against RMB585m of mostly short-term bank debt. Covenant waivers and a going-concern note mean the equity is effectively an option on management's ability to turn inventory into cash while banks keep rolling facilities.
The 1H2026 data are the first encouraging sign in two years: 30% revenue growth, a near-breakeven result and RMB123m of operating cash flow. They also confirm that the recovery is volume bought through price, with gross margin at 14.2%.
At 0.59x book and about 1.1x EV/sales, the market is pricing persistent sub-par returns plus some refinancing risk, and that is defensible. A re-rating requires three things together:
-
carrageenan margins recovering to the high teens;
-
a durable cut in inventory days to below 300;
-
visible revenue from the agarose and algae-membrane bets.
Until at least two of these are evident in FY2026 results, the stock is best viewed as a speculative, cyclical deep-value situation with elevated balance-sheet and governance risk. Stance: Neutral / Speculative Hold, with balance-sheet monitorables as the primary trigger for revision.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Age | With group since | Background / prior roles | Education |
|---|---|---|---|---|---|
CHAN Kam Chung | Executive Director, Chairman & CEO; chairs Nomination Committee; member of Remuneration Committee | 55 | May 2003 | Director/Deputy GM of Guangda (Fujian) Foodstuff (1998–2001); honorary president of China Algae Industry Association Carrageenan Branch (2019) | Part-time food-technology courses, Zhangzhou Institute of Technology (2013); HKU SPACE executive programme (2016) |
GUO Dongxu | Executive Director, Vice Chairman & Vice President (project development, QC, external affairs) | 58 | Mar 2009 | Executive director, South Fujian Agar Co. (1995–2018); GM of Lvqi (Fujian); president of China Algae Industry Association Carrageenan Branch (2019) | Part-time courses, Zhangzhou Institute of Technology |
CHAN Shui Yip | Executive Director, Vice Chairman & Vice President (product management, sourcing, HR, administration) | 64 | Mar 1999 | Deputy manager, Jinjiang Xinyi Leather & Plastic (1988–1999). Elder brother of Chan Kam Chung | PKU Shenzhen advanced business administration (2017); Renmin University finance course (2018) |
SHE Xiaoying | Executive Director (sales) | 64 | May 2003 | Production manager, Jinjiang Xinyi (1988–2003); former GM of Green Fresh (Fujian). Brother-in-law of both Chans | — |
CHEN Yi (Ms.) | Executive Director (from 7 Jun 2024); VP (Management: HR, admin, IT) | 38 | May 2019 | HR & admin manager, AB InBev Sedrin (Zhangzhou) Brewery (2011–2019) | BA Fujian Agriculture & Forestry University (2011); MBA Hongkong Finance & Economics College (2022) |
HO Kwai Ching, Mark | INED; chairs Audit Committee | 64 | Listing (2019) | Ex-HKEX VP Corporate Strategy; ex-COO Oriental Patron Securities; CEO of ProMEX; INED of Lee Kee, Hengan International, Everbright Grand China Assets (from 19 Nov 2025) | BSocSc HKU (1984); FCCA, FHKICPA |
NG Man Kung | INED; chairs Remuneration Committee | 74 | Listing (2019) | Chief executive of Chiyu Banking Corp (1992–2012); INED of Fujian Holdings and ELL Environmental | Banking extension course, HK PolyU |
HU Guohua | INED; Audit Committee and Nomination Committee (from 27 Jun 2025) | 52 | Listing (2019) | Hydrocolloid and food-additive specialist; Secretary General, Sweet Flavouring Committee (China Food Additives & Ingredients Assoc.); INED of Zhejiang Shengda Bio-pharm, Anhui JinHe, Touyun Biotech | BSc, MSc Nanchang University; PhD (Eng.) East China University of Science & Technology (2006) |
“—” = not publicly disclosed.
Board & Management Changes
| Date | Change |
|---|---|
17 Jul 2023 | NED Guo Songsen resigned after an SFC enquiry revealed Model Code breaches (dealings in the 2022 and 2023 blackout periods) |
7 Jun 2024 | Ms. Chen Yi appointed Executive Director |
27 Jun 2025 | Chen Yi and Hu Guohua appointed to the Nomination Committee |
19 Nov 2025 | Ho Kwai Ching additionally appointed INED of Everbright Grand China Assets |
Major Shareholders
| Holder | Vehicle | Shares | % |
|---|---|---|---|
Chan Kam Chung | COS Kreation Investment Development Co. | 161,700,000 | 18.50 |
Chan Shui Yip | Epoch Investment Development Co. | 161,700,000 | 18.50 |
Guo Songsen | Green Forest (BVI) Investment Co. (plus 866,000 direct) | 92,603,571 | 10.59 |
Guo Dongxu | Strong Achievement (BVI) Investment Co. | 66,150,000 | 7.57 |
Guo Yuansuo | Winning Path Trading Co. | 66,150,000 | 7.57 |
Guo Donghuang | East Prosperity (BVI) Investment Co. | 39,696,429 | 4.54 |
Concert group total | — | 588,000,000 | 67.27 |
Chen Yi (director) | Direct (incl. unvested awards) | 818,000 | 0.09 |
Share award trust | Trustee | ~8.4m shares (book cost RMB8.4m); 6.53m available for grant | ~0.75 |
Public float | — | ≥25% confirmed | ~32 |
Competitive Landscape
Key Competitors
| Competitor | HQ | Segments competing | Relative positioning | Revenue (latest) |
|---|---|---|---|---|
CP Kelco (part of Tate & Lyle since 15 Nov 2024) | US / UK | Carrageenan, pectin, specialty gums | Global premium texturant leader; applications labs; multinational customer base | Tate & Lyle FY Mar-2026 revenue £2,006m (CP Kelco revenue implied ~US$700m from the "10% = ~US$70m" synergy target) |
Ingredion (bidder for Tate & Lyle, May 2026) | US | Texturants (starches, gums, via proposed T&L/CP Kelco combination) | Scale texturiser; potential mega-consolidator | — |
IFF (Nourish) | US | Carrageenan and other texturants (legacy DuPont/FMC portfolio) | Global multinational supplier | — |
Cargill (texturizing solutions) | US | Carrageenan, pectin, alginates | Global, vertically integrated | Private — not disclosed |
Ceamsa | Spain | Carrageenan, pectin | European specialist | Private — not disclosed |
Gelymar | Chile | Carrageenan | South American seaweed-integrated | Private — not disclosed |
W Hydrocolloids / Shemberg / Marcel Carrageenan / TBK | Philippines | Carrageenan (refined and semi-refined) | Origin-based processors close to Eucheuma supply | Private — not disclosed |
Ina Food Industry | Japan | Agar | Leading Japanese agar maker; premium | Private — not disclosed |
Hispanagar / Iberagar / B&V Agar | Spain / Portugal / Italy | Agar, agarose (B&V in lab agar) | European agar specialists | Private — not disclosed |
Fujian and Shandong regional peers (e.g., Shishi-based agar processors; Qingdao algae processors) | China | Agar, carrageenan | Domestic price competition ("involution") | — |
Hubei-based konjac processors (e.g., Yizhi Konjac) | China | Konjac gum | Domestic konjac leaders | — |
“—” = not publicly disclosed.
Competitive Advantages & Vulnerabilities
| Advantages | Vulnerabilities |
|---|---|
Scale in agar plus carrageenan (27,390 t capacity) and a dual seaweed-origin footprint (China + Indonesia) | Commodity exposure: earnings swing with seaweed prices; FY2023 loss |
Low-cost Indonesian semi-refined carrageenan | Small R&D budget (RMB28.7m) vs multinationals |
Breadth across four colloids enables blends | Balance-sheet stretch: 398-day CCC, net debt/EBITDA 5.8x, covenant waivers |
Standards-setting role and HNTE status | Customer concentration modest, but supplier concentration high (top-5 suppliers 53%) |
Quick-dissolve agar and agarose niches | Thin Western brand presence; North America only 2.3% of sales |
Founder-aligned controlling shareholders (67%) | Weak governance optics: combined Chair/CEO, family board, prior Model Code breach |
Peer Comparison FY2025
| Metric | Green Fresh Bio (FY2025) | Tate & Lyle incl. CP Kelco (FY Mar-2026) |
|---|---|---|
Revenue | RMB904.7m (~US$126m, computed) | £2,006m |
Revenue growth | −8.6% | +16% statutory; −3% pro forma |
Gross margin | 18.5% | — |
Net margin | 0.6% | — |
R&D intensity | 3.2% | — |
Recent Developments
--



